葉酸サプリメントに循環器疾患の再発予防効果はない
- 2006-12-17 - これまでに実施された12の無作為化試験のデータをメタ解析したところ、心血管疾患の既往を有する患者が葉酸サプリメントを服用しても心血管疾患のリスクは軽減しないという結果が得られました。 (2 段落, 147 文字)
- [全文を読むには有料会員登録が必要です]
- [有料会員登録がお済みの方はログインしてください]
- [メールマガジン（無料）をご利用ください]
全文記事サンプル [全文読める記事の一覧です]
関連ニュース
2020-02-19|循環器疾患全般
+ 労して遺伝子情報を得たところで心疾患リスク予想は全くまたは大して改善せず
2020-02-02|循環器疾患全般
+ LPL活性を両極端から助けるCorvidia社ペプチド薬でマウスのトリグリセリド減少
2020-01-25|循環器疾患全般
+ 危険に応じたアドレナリン分泌が心拍を高める仕組みの一翼を担う蛋白質が判明
2019-12-05|循環器疾患全般
+ 運動時の循環前駆細胞(CPC)測定は冠疾患患者の予後予想により有益
2019-12-04|循環器疾患全般
+ 非HDLコレステロール値が高いほど冠疾患や脳卒中を被り易い
コメント一覧
2006-12-17 | 投稿者 ： 清宮さん
メタ解析の結果、葉酸に心血管疾患の二次予防効果はないと示唆されました。
▽葉酸サプリメントに循環器疾患の再発予防効果はない
http://www.biotoday.com/view.cfm?n=16906
現在葉酸の心血管疾患予防作用を検討しているいくつかの大規模試験が実施されています(1)-(9)。
これらの大規模試験の結果で葉酸の心血管疾患予防効果に関する評価が定まると考えられます。
(1)Bassuk SS, Albert CM, Cook NR, et al. The Women's Antioxidant Cardiovascular Study: design and baseline characteristics of participants. J Womens Health (Larchmt). 2004;13:99-117.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=15006283&dopt=Abstract
(2)Jamison RL, Hartigan P, Gaziano JM, et al. Design and statistical issues in the Homocysteinemia in Kidney and End Stage Renal Disease (HOST) study. Clin Trials. 2004;1:451-460.
http://ctj.sagepub.com/cgi/content/abstract/1/5/451?ijkey=
\ne1df36f08b7c189cea2bf7f6cadd7a31bd3e087d&keytype2=tf_ipsec
\nsha
(3)MacMahon M, Kirkpatrick C, Cummings CE, et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis. 2000;10:195-203.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=11079257&dopt=Abstract
(4)Bostom AG, Carpenter MA, Kusek JW, et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J. 2006;152:448-453.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=16923411&dopt=Abstract
(5)Bleie O, Refsum H, Ueland PM, et al. Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention. Am J Clin Nutr. 2004;80:641-648.
http://www.ajcn.org/cgi/content/abstract/80/3/641?ijkey=e9
\nb64f1be8526654636b7ed0b10793f2590d7336&keytype2=tf_ipsecsh
\na
(6)Galan P, de Bree A, Mennen L, et al. Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging. 2003;7:428-435.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=14625623&dopt=Abstract
(7)VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002;13:120-126.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=11867886&dopt=Abstract
(8)B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151:282-287.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=16442889&dopt=Abstract
(9)Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
http://jama.ama-assn.org/cgi/content/abstract/288/16/2015?
\nijkey=a99e14b30df1152483981dd7da4c9da58710e8c6&keytype2=tf
\n_ipsecsha
▽葉酸サプリメントに循環器疾患の再発予防効果はない
http://www.biotoday.com/view.cfm?n=16906
現在葉酸の心血管疾患予防作用を検討しているいくつかの大規模試験が実施されています(1)-(9)。
これらの大規模試験の結果で葉酸の心血管疾患予防効果に関する評価が定まると考えられます。
(1)Bassuk SS, Albert CM, Cook NR, et al. The Women's Antioxidant Cardiovascular Study: design and baseline characteristics of participants. J Womens Health (Larchmt). 2004;13:99-117.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=15006283&dopt=Abstract
(2)Jamison RL, Hartigan P, Gaziano JM, et al. Design and statistical issues in the Homocysteinemia in Kidney and End Stage Renal Disease (HOST) study. Clin Trials. 2004;1:451-460.
http://ctj.sagepub.com/cgi/content/abstract/1/5/451?ijkey=
\ne1df36f08b7c189cea2bf7f6cadd7a31bd3e087d&keytype2=tf_ipsec
\nsha
(3)MacMahon M, Kirkpatrick C, Cummings CE, et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis. 2000;10:195-203.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=11079257&dopt=Abstract
(4)Bostom AG, Carpenter MA, Kusek JW, et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J. 2006;152:448-453.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=16923411&dopt=Abstract
(5)Bleie O, Refsum H, Ueland PM, et al. Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention. Am J Clin Nutr. 2004;80:641-648.
http://www.ajcn.org/cgi/content/abstract/80/3/641?ijkey=e9
\nb64f1be8526654636b7ed0b10793f2590d7336&keytype2=tf_ipsecsh
\na
(6)Galan P, de Bree A, Mennen L, et al. Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging. 2003;7:428-435.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=14625623&dopt=Abstract
(7)VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002;13:120-126.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=11867886&dopt=Abstract
(8)B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151:282-287.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve
\n&db=pubmed&list_uids=16442889&dopt=Abstract
(9)Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
http://jama.ama-assn.org/cgi/content/abstract/288/16/2015?
\nijkey=a99e14b30df1152483981dd7da4c9da58710e8c6&keytype2=tf
\n_ipsecsha
メール会員登録（無料）をされますと、BioTodayに登録された記事を毎日メールでお知らせします。また、メール会員登録されますと、毎週月曜からの一週間あたり2つの記事の全文閲覧が可能になります。
新着ニュース